| Primary information |
|---|
| sequence ID | Seq_1704 |
| Peptide sequence | EDPQGDAAQKTD |
| CancerPDF_ID | CancerPDF_ID9500, CancerPDF_ID13852, CancerPDF_ID13853, |
| PMID | 21533267,20974924,20974924 |
| Protein Name | Alpha-1-antitrypsin,Putative alpha-1-antitrypsin-related protein,Putative alpha-1-antitrypsin-related protein |
| UniprotKB Entry Name | A1AT_HUMAN,A1ATR_HUMAN,A1ATR_HUMAN |
| Fluid | Serum,Plasma,Plasma |
| M/Z | 637.76,1274.55,1274.55 |
| Charge | 2,2,2 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | LC/MS/MS,LC-MS/MS,LC-MS/MS |
| Quantification Technique | Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | 1.49,NA,NA |
| CancerPDF_ID | CancerPDF_ID9500, CancerPDF_ID13852, CancerPDF_ID13853, |
| p-Value | NA,NA,NA |
| Software | MASCOT,MASCOT and SEQUEST,MASCOT and SEQUEST |
| Length | 12,NA,NA |
| Cancer Type | Lung adenocarcinoma,"Multiple myeloma patients, Acute myeloid leukemia","Multiple myeloma patients, Acute myeloid leukemia" |
| Database | Swissprot Database (57.4),Uniprot database,Uniprot database |
| Modification | NA,NA,NA |
| Number of Patients | 62 lung adenocarcinoma and 30 healthy control,NA,NA |
| Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",NA,NA |
| Validation | MRM-based validation of 19 candidates,NA,NA |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |